A UK study found that using a polygenic risk score to identify men at highest genetic risk of prostate cancer significantly ...

Revenue and Sales Performance: For the fiscal third quarter of 2025, Biomerica reported net sales of $1.10 million, a 10% increase from $1.00 million recorded in the same quarter of the previous year.

YearDelivers Improved Gross Margins, Achieves Annual Cost Savings Target Early, and Reduces Cash Burn Over 55% IRVINE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- ...

SYNLAB Nigeria, a leader in medical diagnostics, is at the forefront of this critical process, ensuring that individuals and ...

Given the opportunity to screen for prostate cancer with a prostate-specific antigen (PSA) test, a significant number ... and 20 years of follow-up. The results indicate that roughly 1 in 6 ...

This randomized, double-blind, placebo-controlled Phase III trial was designed to test the efficacy ... of-study biopsy if serum PSA levels fell within a prespecified range. Prostate cancer ...

A new form of focal therapy for prostate cancer has made its way to the Natural State, set to be offered by the University of Arkansas for Medical Sciences.Nano ...

A polygenic risk score identified more clinically significant prostate cancer cases than PSA or MRI in the BARCODE1 trial. The study involved 6393 participants, with 745 invited for screening based on ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ETCompany ParticipantsMike Comilla - VP, IRRobert Ford - Chairman ...

Artificial intelligence can help urologists and oncologists make treatment recommendations that are objective and evidence-based.